-
Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes
Friday, April 9, 2021 - 6:30am | 398Read More...Provention Bio Inc (NASDAQ: PRVB) revealed it had received a notification on April 2 from the FDA stating that the agency has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. Notably, the FDA expressed...
-
Ocuphire Pharma Starts Mid-Stage APX3330 Study In Diabetic Retinopathy Patients
Thursday, April 8, 2021 - 10:43am | 259Read More...Ocuphire Pharma Inc (NASDAQ: OCUP) has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (mild PDR). Effects on diabetic macular edema will be explored as...
-
Strongbridge's Recorlev Shows Improvements in Cortisol Control In Cushing's Syndrome, Diabetes
Thursday, April 8, 2021 - 6:52am | 301Read More...Results from a sub-analysis of patients with diabetes mellitus from Phase 3 SONICS study evaluating Strongbridge Biopharma plc's (NASDAQ: SBBP) Recorlev (levoketoconazole) for endogenous Cushing's syndrome were published in Frontiers in Endocrinology....
-
Biolojic Inks Research And Licensing Pact With Eli Lilly For Diabetes Antibody Therapies
Tuesday, March 9, 2021 - 10:11am | 227Read More...Eli Lilly and Co (NYSE: LLY) and Biolojic Design Ltd have entered into a research collaboration and license agreement to discover and develop antibody-based therapy for diabetes. The agreement will leverage Biolojic's AI-based multibody platform. Specific targets...
-
Eli Lilly's Tirzepatide Tops Novo's Semaglutide In Late-Stage Diabetes Study
Thursday, March 4, 2021 - 12:40pm | 486Read More...Eli Lilly & Co (NYSE: LLY) has reported positive results from another Phase 3 trial evaluating tirzepatide in Type 2 diabetics. The dual GIP/GLP-1 agonist beat Novo Nordisk A/S’s (NYSE: NVO) semaglutide against multiple measures. Recently, Lilly...
-
Eli Lilly's Tirzepatide Reduces A1C And Body Weight, Late-Stage Studies In Type 2 Diabetes Show
Wednesday, February 17, 2021 - 9:58am | 425Read More...Eli Lilly And Co (NYSE: LLY) have announced topline results from two Phase 3 studies, SURPASS-3 and SURPASS-5, evaluating Tirzepatide in adults with type 2 diabetes. Data showed that Tirzepatide led to significant A1C and body weight reductions from baseline...
-
COVID-19 May Trigger Diabetes: Can Marijuana Help?
Sunday, June 28, 2020 - 12:50pm | 789Read More...By The Fresh Toast's Kate-Madonna Hindes, provided exclusively to Benzinga Cannabis. Researchers believe that some people may develop diabetes for the first time due to contracting severe COVID-19. Here’s how cannabis may help. There are some new, unanswered questions about the busy...
-
Provention Bio's CEO On Identifying Autoimmune Diseases 'Before It's Too Late'
Tuesday, May 5, 2020 - 11:28am | 953Read More...When it comes to treating chronic, immune-mediated diseases, the standard course is to wait for symptoms before beginning treatment. But by that point, it may be too late for intervention. These diseases can silently do irreversible damage, according to Provention Bio Inc (NASDAQ: PRVB) CEO...
-
VTV Therapeutics 'Close To The Finish Line' On What FDA, Diabetes Patients Want: An Adjunct Therapy To Insulin
Wednesday, February 19, 2020 - 11:48am | 899Read More...Steve Holcombe transitioned from telecom to biotech back when vTv Therapeutics Inc (NASDAQ: VTVT) was just a startup. Now, 18 years in, he’s finally seeing the fruits of his labor. “We’re getting close to the finish line,” Holcombe, the CEO of VTV, told Benzinga. “We...
-
VTV Therapeutics Shares Hit 16-Month High After Diabetes Drug Aces Midphase Study
Monday, February 10, 2020 - 12:14pm | 453Read More...Shares of micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) were advancing to their highest level since October 2018 Monday following a clinical readout from the company. Success In Phase 2 For VTV Therapeutics High Point, North Carolina-based vTv said part two of the Phase 2 Simplici-...
-
Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin
Wednesday, December 18, 2019 - 12:07pm | 756Read More...Eli Lilly And Co (NYSE: LLY) CEO David Ricks said Tuesday that U.S. Sen. Elizabeth Warren’s criticism of the cost of the drugmaker's insulin is “nonsense.” Warren Says Eli Lilly Broke Promise On Insulin In a Monday Facebook post, the Democratic presidential candidate denounced...
-
Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline
Tuesday, September 17, 2019 - 4:35pm | 1408Read More...The thinly traded micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) is on investors' radars ahead of a Sept. 18 poster presentation of clinical data. The company is set to present at the European Association for the Study of Diabetes 55th annual meeting with results from the Part...
-
Morgan Stanley: Buy The Dip In Livongo Health
Wednesday, August 28, 2019 - 2:23pm | 404Read More...Shares of Livongo Health Inc (NASDAQ: LVGO) have lost nearly 20% since its late July IPO, and investors should take advantage of the discount valuation, according to Morgan Stanley. The Analyst Ricky Goldwasser upgraded Livongo Health from Equal-weight to Overweight with an unchanged $42 price...
-
Midatech Pharma Rallies On Positive MTX102 Results
Friday, July 19, 2019 - 2:33pm | 260Read More...Midatech Pharma PLC-ADR (NASDAQ: MTP) shares were trading higher Friday after the company announced positive results from a first-in-human study of its MTX102 immuno-tolerizing vaccine product candidate in diabetes. The results showed that MTX102 was well-tolerated, with asymptomatic local...
-
The Science On How Cannabis Could Help Diabetes Patients
Wednesday, October 17, 2018 - 3:28pm | 826Read More...Weed's role as a natural painkiller without the addictive properties of opioids is well-known, as is cannabidiol's helpfulness in combating seizures and anxiety. Studies and evidence support CBD's effectiveness in improving the behavior of children on the autism spectrum...
